Retargeting Strategies for Oncolytic Herpes Simplex Viruses

Published on Feb 26, 2016in Viruses3.811
· DOI :10.3390/v8030063
Gabriella Campadelli-Fiume41
Estimated H-index: 41
Biljana Petrovic5
Estimated H-index: 5
+ 4 AuthorsValentina Gatta4
Estimated H-index: 4
Most of the oncolytic herpes simplex viruses (HSVs) exhibit a high safety profile achieved through attenuation. They carry defects in virulence proteins that antagonize host cell response to the virus, including innate response, apoptosis, authophagy, and depend on tumor cell proliferation. They grow robustly in cancer cells, provided that these are deficient in host cell responses, which is often the case. To overcome the attenuation limits, a strategy is to render the virus highly cancer-specific, e.g., by retargeting their tropism to cancer-specific receptors, and detargeting from natural receptors. The target we selected is HER-2, overexpressed in breast, ovarian and other cancers. Entry of wt-HSV requires the essential glycoproteins gD, gH/gL and gB. Here, we reviewed that oncolytic HSV retargeting was achieved through modifications in gD: the addition of a single-chain antibody (scFv) to HER-2 coupled with appropriate deletions to remove part of the natural receptors’ binding sites. Recently, we showed that also gH/gL can be a retargeting tool. The insertion of an scFv to HER-2 at the gH N-terminus, coupled with deletions in gD, led to a recombinant capable to use HER-2 as the sole receptor. The retargeted oncolytic HSVs can be administered systemically by means of carrier cells-forcedly-infected mesenchymal stem cells. Altogether, the retargeted oncolytic HSVs are highly cancer-specific and their replication is not dependent on intrinsic defects of the tumor cells. They might be further modified to express immunomodulatory molecules.
  • References (86)
  • Citations (14)
📖 Papers frequently viewed together
775 Citations
20033.75Gene Therapy
12 Authors (Binlei Liu, ..., Robert S. Coffin)
408 Citations
20 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1S. K. GeevargheseH-Index: 1
#2A. ChenH-Index: 1
Last. Kenneth K. TanabeH-Index: 69
view all 10 authors...
4089 Background: NV1020 is a genetically engineered oncolytic Herpes virus. Published Phase 1 dose-ranging results reported no significant related toxicity except for a mild (<24 hr) viral syndrome. Initial Phase 2 tumor response data using the optimal biological dose (OBD) are now presented. Methods: Patients with heavily pretreated, progressing liver mCRC received 4 doses of NV1020 (1 X108 pfu) by weekly hepatic artery infusion followed by two cycles of conventional chemotherapy. Follow-up (≥1...
1 Citations
#1Valerio LeoniH-Index: 8
#2Valentina Gatta (UNIBO: University of Bologna)H-Index: 28
Last. Gabriella Campadelli-Fiume (UNIBO: University of Bologna)H-Index: 41
view all 13 authors...
// Valerio Leoni 1,* , Valentina Gatta 1,* , Arianna Palladini 1 , Giordano Nicoletti 1 , Dario Ranieri 1 , Massimiliano Dall’Ora 1 , Valentina Grosso 1 , Martina Rossi 1 , Francesco Alviano 1 , Laura Bonsi 1 , Patrizia Nanni 1 , Pier-Luigi Lollini 1 and Gabriella Campadelli-Fiume 1 1 Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy * These authors have contributed equally to this work Correspondence to: Gabriella Campadelli-Fiume, email: // Pi...
25 CitationsSource
#1Robert H.I. Andtbacka (UofU: University of Utah)H-Index: 28
#2Howard L. Kaufman (RU: Rutgers University)H-Index: 49
Last. R. S. Coffin (Amgen)H-Index: 10
view all 29 authors...
775 CitationsSource
#1Katharina Hammer (DKFZ: German Cancer Research Center)H-Index: 3
#2Adam Kazcorowski (DKFZ: German Cancer Research Center)H-Index: 1
Last. Dirk M. Nettelbeck (DKFZ: German Cancer Research Center)H-Index: 32
view all 7 authors...
Oncolytic viruses have demonstrated in pre-clinical and clinical studies safety and a unique pleiotropic activity profile of tumor destruction. Yet, their delivery suffers from virus inactivation by blood components and sequestration to healthy tissues. Therefore, mesenchymal stromal cells (MSCs) have been applied as carrier cells for shielded virus delivery to tumors after ex vivo infection with oncolytic viruses. However, infection and particle production by MSCs have remained unsatisfying. He...
13 CitationsSource
Viruses have been suggested to be useful as anti-cancer agents since the early 20th century, although following the advent of chemotherapy and radiotherapy work largely stopped until the 1990s when a number of groups began to explore the use of engineered viruses. This overview summarizes the development of the field from the 1990s to the present day, an era when oncolytic viruses have now demonstrated clear clinical benefit to patients. The hurdles and challenges which needed to be overcome are...
32 CitationsSource
#1Tatiana Gianni (UNIBO: University of Bologna)H-Index: 15
#2Raffaele Massaro (UNIBO: University of Bologna)H-Index: 1
Last. Gabriella Campadelli-Fiume (UNIBO: University of Bologna)H-Index: 41
view all 3 authors...
Herpes simplex virus (HSV) is an important human pathogen. It enters cells through an orchestrated process that requires four essential glycoproteins, gD, gH/gL, and gB, activated in cascade fashion by receptor-binding and signaling. gH/gL heterodimer is conserved across the Herpesviridae family. HSV entry is enabled by gH/gL interaction with αvβ6- or αvβ8-integrin receptors. We report that the interaction of virion gH/gL with integrins resulted in gL dissociation and its release in the medium. ...
23 CitationsSource
#1Valentina Gatta (UNIBO: University of Bologna)H-Index: 4
#2Biljana Petrovic (UNIBO: University of Bologna)H-Index: 5
Last. Gabriella Campadelli-Fiume (UNIBO: University of Bologna)H-Index: 41
view all 3 authors...
20 CitationsSource
#1Timothy P. Cripe (Nationwide Children's Hospital)H-Index: 30
#2Chun-Yu Chen (Nationwide Children's Hospital)H-Index: 7
Last. Gregory K. Friedman (UAB: University of Alabama at Birmingham)H-Index: 13
view all 13 authors...
Progress for improving outcomes in pediatric patients with solid tumors remains slow. In addition, currently available therapies are fraught with numerous side effects, often causing significant life-long morbidity for long-term survivors. The use of viruses to kill tumor cells based on their increased vulnerability to infection is gaining traction, with several viruses moving through early and advanced phase clinical testing. The prospect of increased efficacy and decreased toxicity with these ...
8 CitationsSource
#1Lucia Mazzacurati (University of Pittsburgh)H-Index: 13
#2Marco Marzulli (University of Pittsburgh)H-Index: 4
Last. Paola Grandi (University of Pittsburgh)H-Index: 17
view all 15 authors...
Glioblastoma multiforme (GBM) is an aggressive brain cancer for which there is no effective treatment. Oncolytic HSV vectors (oHSVs) are attenuated lytic viruses that have shown promise in the treatment of human GBM models in animals, but their efficacy in early phase patient trials has been limited. Instead of attenuating the virus with mutations in virulence genes, we engineered four copies of the recognition sequence for miR-124 into the 3′UTR of the essential ICP4 gene to protect healthy tis...
25 CitationsSource
#1Elizabeth Ilett (Mayo Clinic)H-Index: 18
#2Timothy Kottke (Mayo Clinic)H-Index: 43
Last. Richard Geoffrey Vile (Mayo Clinic)H-Index: 49
view all 13 authors...
Optimum clinical protocols require systemic delivery of oncolytic viruses in the presence of an intact immune system. We show that preconditioning with immune modulators, or loading virus onto carrier cells ex vivo, enhances virus-mediated antitumor activity. Our early trials of systemic reovirus delivery showed that after infusion reovirus could be recovered from blood cells—but not from plasma—suggesting that rapid association with blood cells may protect virus from neutralizing antibody. We t...
27 CitationsSource
Cited By14
#1Zhi‐Qiang Ye (First Affiliated Hospital of Wenzhou Medical University)
#2Chang‐Lin Zou (First Affiliated Hospital of Wenzhou Medical University)
Last. Dian‐Na Gu (First Affiliated Hospital of Wenzhou Medical University)
view all 6 authors...
#1Ceren Tuzmen (University of Pittsburgh)
#2Tina M. Cairns (UPenn: University of Pennsylvania)H-Index: 19
Last. Joseph C. Glorioso (University of Pittsburgh)H-Index: 63
view all 9 authors...
Abstract Effective oncolytic virotherapy may require systemic delivery, tumor targeting and resistance to virus neutralizing (VN) antibodies. Since HSV glycoprotein D is the viral attachment/entry protein and predominant VN target, we examined the impact of gD retargeting alone and in combination with alterations in dominant VN epitopes on virus susceptibility to VN antibodies. We compared the binding of a panel of anti-gD monoclonal antibodies (mAbs) that mimic antibody specificities in human H...
#1Faith Howard (University of Sheffield)
#2Munitta Muthana (University of Sheffield)H-Index: 16
#1Francesco Alessandrini (UniGe: University of Genoa)H-Index: 3
#2Laura Menotti (UNIBO: University of Bologna)H-Index: 17
Last. Paolo Malatesta (UniGe: University of Genoa)H-Index: 15
view all 8 authors...
Oncolytic herpes simplex viruses are proving to be effective in clinical trials against a number of cancers. Here, R-115, an oncolytic herpes simplex virus retargeted to human erbB-2, fully virulent in its target cells, and armed with murine interleukin-12 was evaluated in a murine model of glioblastoma. We show that a single R-115 injection in established tumors resulted, in about 30% of animals, in the complete eradication of the tumor, otherwise invariably lethal. The treatment also induced a...
3 CitationsSource
#1Reena Goswami (United States Army Medical Research Institute of Chemical Defense)
#2Gayatri Subramanian (UT: University of Toledo)H-Index: 1
Last. Venkaiah Betapudi (Case Western Reserve University)H-Index: 11
view all 10 authors...
The human genetic code is the vehicle that drives the synthesis of proteins necessary for life-sustaining biological processes. Though the genetic ciphering remains unchanged through generations, some genes get disrupted, deleted and/or mutated, manifested as diseases and disorders. Current treatment options—chemotherapy, protein therapy, radiotherapy, and surgery available for less than 500 diseases—neither cure nor prevent genetic errors, but rather, often cause many side effects. However, gen...
#1Alberto Reale (UNIPD: University of Padua)H-Index: 1
#2Adriana Vitiello (UNIPD: University of Padua)H-Index: 1
Last. Giorgio Palù (UNIPD: University of Padua)H-Index: 58
view all 6 authors...
Background With few exceptions, current chemotherapy and radiotherapy protocols only obtain a slightly prolonged survival with severe adverse effects in patients with advanced solid tumors. In particular, most solid malignancies not amenable to radical surgery still carry a dismal prognosis, which unfortunately is also the case for relapsing disease after surgery. Even though targeted therapies obtained good results, clinical experience showed that tumors eventually develop resistance. On the ot...
1 CitationsSource
#1Jonathan Pol (UPMC: Pierre-and-Marie-Curie University)H-Index: 16
#2Sarah Levesque (UPMC: Pierre-and-Marie-Curie University)H-Index: 6
Last. Lorenzo Galluzzi (Cornell University)H-Index: 94
view all 15 authors...
ABSTRACTOncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, w...
9 CitationsSource
#1Sara ArtusiH-Index: 1
#2Yoshitaka MiyagawaH-Index: 18
Last. Joseph C. GloriosoH-Index: 63
view all 5 authors...
Neurodegenerative diseases (NDs) have a profound impact on human health worldwide and their incidence is predicted to increase as the population ages. ND severely limits the quality of life and leads to early death. Aside from treatments that may reduce symptoms, NDs are almost completely without means of therapeutic intervention. The genetic and biochemical basis of many NDs is beginning to emerge although most have complex etiologies for which common themes remain poorly resolved. Largely rely...
4 CitationsSource
#1Valerio Leoni (UNIBO: University of Bologna)H-Index: 8
#2Andrea Vannini (UNIBO: University of Bologna)H-Index: 7
Last. Gabriella Campadelli-Fiume (UNIBO: University of Bologna)H-Index: 41
view all 11 authors...
Oncolytic herpes simplex viruses (oHSVs) showed efficacy in clinical trials and practice. Most of them gain cancer-specificity from deletions/mutations in genes that counteract the host response, and grow selectively in cancer cells defective in anti-viral response. Because of the deletions/mutations, they are frequently attenuated or over-attenuated. We developed next-generation oHSVs, which carry no deletion/mutation, gain cancer-specificity from specific retargeting to tumor cell receptors—e....
10 CitationsSource
#1Laura Menotti (UNIBO: University of Bologna)H-Index: 17
#2Elisa Avitabile (UNIBO: University of Bologna)H-Index: 21
Last. Gabriella Campadelli-Fiume (UNIBO: University of Bologna)H-Index: 41
view all 6 authors...
Previously, we engineered oncolytic herpes simplex viruses (o-HSVs) retargeted to the HER2 (epidermal growth factor receptor 2) tumor cell specific receptor by the insertion of a single chain antibody (scFv) to HER2 in gD, gH, or gB. Here, the insertion of scFvs to three additional cancer targets—EGFR (epidermal growth factor receptor), EGFRvIII, and PSMA (prostate specific membrane antigen)—in gD Δ6–38 enabled the generation of specifically retargeted o-HSVs. Viable recombinants resulted from t...
5 CitationsSource